Stock Research Report for Panacea Biotec Ltd
Stock score of Panacea Biotec Ltd moved up by 1 in a week on a 10 point scale (Source: Refinitiv). Get detailed report on Panacea Biotec Ltd by subscribing to ETPrime.
![Stock Reports Plus Stock Reports Plus](https://img.etimg.com/thumb/msid-83539106,width-462,height-284,imgsize-445470,resizemode-8,quality-100/stock-reports-plus.jpg)
Get 4000+ Stock Reports worth₹ 1,499* with ETPrimeat no extra cost for you
*As per competitive benchmarking of annual price. T&C apply
Make Investment decisions
with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum
Find new Trading ideas
with weekly updated scores and analysts forecasts on key data points
In-Depth analysis
of company and its peers through independent research, ratings, and market data
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.